Dr. Brown is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# Dana-Far
Boston, MA 02115Phone+1 617-632-4894Fax+1 617-582-7909
Education & Training
Brigham and Women's HospitalResidency, Internal Medicine, 2017- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2001
Harvard Medical SchoolClass of 1998
Certifications & Licensure
MA State Medical License 2000 - 2026
MS State Medical License 2017 - 2021- American Board of Internal Medicine Hematology
Clinical Trials
- Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Start of enrollment: 2003 Dec 01
- Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Start of enrollment: 2005 Feb 01
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Start of enrollment: 2004 Aug 09
- Join now to see all
Publications & Presentations
PubMed
- Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.Abi Vijenthira, Virginia O Volpe, Aswin Sekar, Roberta Santos Azevedo, Mariia Mikhaleva
Blood Advances. 2024-12-10 - COVID-19 vaccination during therapy in relation to COVID-19 death in CLL.Jennifer R Brown, Simon Rule, Kara Miller, John F Seymour
Blood Advances. 2024-10-22 - Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03
Abstracts/Posters
- Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLLJennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline SettingDecember 9th, 2024- Acalabrutinib Plus Venetoclax Improves PFS in First-of-Its-Kind CLL TrialDecember 9th, 2024
- Promising Results with Epcoritamab Monotherapy in Relapsed/Refractory CLLDecember 8th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
